Brief: Shenzhen Hepalink Pharmaceutical Says Unit Entered Into Share Transfer Agreement With, Among Others, Sanofi Foreign Participations BV
11/01/2021 14:53
Jan 11 (Reuters) - Shenzhen Hepalink Pharmaceutical Group Co
Ltd 002399.SZ :
* UNIT ENTERED INTO SHARE TRANSFER AGREEMENT WITH, AMONG
OTHERS,
SANOFI FOREIGN PARTICIPATIONS BV
* SANOFI FOREIGN PARTICIPATIONS TO ACQUIRE 8.66% OF KYMAB
GROUP
FROM UNIT
* UPFRONT TOTAL PAYMENT TO ACQUIRE ALL OF EQUITY INTEREST OF
KYMAB
US$1,100 MILLION
Source text for Eikon: ID:nHKS2Kvd5Z
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA